Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Drug Profile

Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Alternative Names: NNZ-2591

Latest Information Update: 22 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Cyclic peptides; Neuroprotectants; Piperazines; Small molecules
  • Mechanism of Action Cell death inhibitors; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pitt-Hopkins syndrome; Angelman syndrome; Telomeric 22q13 Monosomy Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Angelman syndrome; Autistic disorder; Cognition disorders; Fragile X syndrome; Multiple sclerosis; Neurological disorders; Parkinson's disease; Peripheral nervous system diseases; Pitt-Hopkins syndrome; Stroke; Telomeric 22q13 Monosomy Syndrome

Most Recent Events

  • 31 Oct 2019 Neuren Pharmaceuticals plans a phase II trials for NNZ 2591 in Angelman syndrome, Pitt-Hopkins syndrome and Telomeric 22q13 Monosomy syndrome (Phelan-McDermid syndrome) in the second half of 2020
  • 17 Oct 2019 NNZ 2591 receives Orphan Drug status for Pitt-Hopkins syndrome in USA
  • 17 Oct 2019 NNZ 2591 receives Orphan Drug status for Telomeric 22q13 Monosomy Syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top